Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Anterra Capital

Investor type Venture Capital
Founders Adam Anders Maarten Goossens Philip Austin

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 26
Average round size
info
The average size of a deal this fund participated in
$19M
Portfolio companies 16
Rounds per year 2.89
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.38
Exits 1
Key employees 7
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Farming
  • Agriculture
  • Veterinary
  • Software
Summary

Anterra Capital is the famous VC, which was founded in 2013. The leading representative office of defined VC is situated in the Amsterdam. The fund was located in Europe if to be more exact in The Netherlands.

This organization was formed by Adam Anders, Maarten Goossens, Philip Austin. Besides them, we counted 6 critical employees of this fund in our database.

Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Caribou Biosciences, Vestaron Corporation, Smartwyre. Among the most popular fund investment industries, there are Service Industry, GreenTech. The fund has exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2016. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 39 percentage points more often commits exit comparing to other organizations.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Anterra Capital, startups are often financed by Unilever Ventures, Pangaea Ventures, Open Prairie. The meaningful sponsors for the fund in investment in the same round are Pangaea Ventures, Open Prairie, Cultivian Sandbox Ventures. In the next rounds fund is usually obtained by Wheatsheaf Group, Pangaea Ventures, Open Prairie.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Anterra Capital:
Typical Co-investors
Anterra Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Anterra Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Cascadia Pacific Kirkland, United States, Washington
China Biomedical Fund Phase I -
Chuangke Accelerated Investment China, Hangzhou, Zhejiang
DRS Chiyoda, Japan
Gaz de France -
Maropost Ventures -
SCP Worldwide New York, New York, United States
SGI Venture Capital Seoul, Seoul-t'ukpyolsi, South Korea
Siena Holding -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Dalma.

Health Insurance
Insurance
Pet
$17M02 Jun 2022 Paris, Ile-de-France, France

Invetx

Biopharma
Biotechnology
Veterinary
$60M10 May 2022 Boston, Massachusetts, United States

Smartwyre

AgTech
SaaS
Software
$10M09 Sep 2021 Denver, Colorado, United States

Slingshot Biosciences

Biotechnology
Medical
Therapeutics
$23M22 Jul 2021 Emeryville, California, United States

ProducePay

Agriculture
Farming
Financial Services
FinTech
Payments
$43M20 May 2021 Los Angeles, California, United States

Vestaron

Agriculture
Biotechnology
Farming
$18M11 Feb 2021 Durham, North Carolina, United States

Invetx

Biopharma
Biotechnology
Veterinary
$10M30 Sep 2020 Boston, Massachusetts, United States

Enko Chem

Agriculture
AgTech
Biotechnology
Chemical
$45M26 Jun 2020 Woburn, Massachusetts, United States

Biotechnology
Life Science
$46M27 May 2020 San Diego, California, United States
News
Smartwyre Secures $10.5M Series A to Connect Agricultural Inputs Industry

– Smartwyre secured $10.5M in Series A funding.
– The funding was supported by High Alpha Capital, Anterra Capital, Fall Line Capital, Revolution’s Rise of the Rest fund and Cavallo Ventures.
– For the agricultural inputs industry, Smartwyre is the first platform to provide end-to-end insights from cost management to commercial pricing, improving industry profitability and preventing mismatches between production levels and the actual farmer demand.
– In 2021, companies delivering more than 35% of the agricultural inputs supplied to US farmers use Smartwyre’s platform to manage their product information, pricing or rebate operations.

Slingshot Biosciences Announces $23 Million in Series A Financing

– Slingshot Biosciences closed a $23m Series A financing.
– The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital.
– The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies.
– Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors.
– Slingshot will also invest heavily in its broader adoptive cell therapy and therapeutics platform with this growth financing.
– Cell-derived products comprise the basis of important healthcare technologies worldwide.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Anterra Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: